Patent CA2012312C successfully refreshed from Google Patents.
CA2012312C
Expired / Lapsed
CA
⏱️ 0.0 years remaining
Genetic units for inhibiting the function of rna
Assignee: Boehringer Ingelheim International GmbH
•
Filing: 1990-03-15
•
Granted: 2001-08-14
•
Expires: 2010-03-15
Abstract
Abstract A genetic unit, for inhibiting RNA contains the transcription units necessary for transcription by polymerase III and a DNA coding for inhibiting RNA, which is arranged within the unit in such a way that the transcribed RNA is part of the polymerase III transcript. Using these units it is possible to achieve increased stability of the inhibiting RNA, which may occur in the form of ribozymes or antisense-RNAs, whilst maintaining an undiminished activity. A process for introducing the genetic units into the cell, the use of these units and pharmaceutical preparations containing them are also disclosed.
Inventors
- 👤 Hartmut Beug
- 👤 Max L. Birnstiel
- 👤 Matthew Cotten
- 👤 Ernst Wagner
- 👤 Harald Kandolf
Bibliographic Details
Application Number
—
Jurisdiction
CA
Data Source
google_patents
Last Synchronized
2026-11-07 14:05
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61K; A61K38/00; C07; C07K; C07K2319/00; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/111; C12N2310/12; C12N2310/121
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
85 words
A DNA molecule optionally occurring in multiple copies, containing sections of a gene transcribed by polymerase III, and a DNA sequence coding for an inhibiting RNA molecule characterized in that it contains the transcription units of a tRNA gene necessary for transcription by polymerase III, including sequences which determine the secondary structure of the tRNA, and the DNA sequence coding for an inhibiting RNA molecule is arranged inside the DNA molecule in such a way that the inhibiting RNA molecule is part of the transcript.
Claim 2
Dependent Claim
85 words
A DNA molecule optionally occurring in multiple copies, containing sections of a gene transcribed by polymerase III, and a DNA sequence coding for an inhibiting RNA molecule characterized in that it contains the transcription units of a tRNA gene necessary for transcription by polymerase III, including sequences which determine the secondary structure of the tRNA, and the DNA sequence coding for an inhibiting RNA molecule is arranged inside the DNA molecule in such a way that the inhibiting RNA molecule is part of the transcript.
Claim 3
Dependent Claim
14 words
A DNA molecule according to claim 1, wherein the inhibiting RNA is a ribozyme.
Claim 4
Dependent Claim
15 words
A DNA molecule according to claim 2, wherein the ribozyme is of the "hammerhead" type.
Claim 5
Dependent Claim
14 words
A DNA molecule according to claim 1, wherein the inhibiting RNA is antisense RNA.
Claim 6
Dependent Claim
14 words
A DNA molecule according to claim 1, comprising transcription units of an initiation-met tDNA.
Claim 7
Dependent Claim
13 words
A DNA molecule according to claim 1, comprising transcription units of a tyrtDNA.
Claim 8
Dependent Claim
32 words
A DNA molecule according to any one of claims 1 to 6, comprising the DNA coding for the inhibiting RNA inserted between A block and B block regions of the tRNA gene.
Claim 9
Dependent Claim
14 words
A DNA molecule according to claim 7, wherein the inhibiting RNA is a ribozyme.
Claim 10
Dependent Claim
15 words
A DNA molecule according to claim 8, wherein, the ribozyme is of the "hammerhead" type.
Claim 11
Dependent Claim
39 words
A DNA molecule according to any one of claims 5, 7, 8 and 9, comprising the DNA coding for the inhibiting RNA inserted in the natural ApaI-restriction site between the A and B block regions of the tRNA gene.
Claim 12
Dependent Claim
20 words
A DNA molecule according to claim 6, comprising the DNA coding for the inhibiting RNA as part of an intron.
Claim 13
Dependent Claim
35 words
A DNA molecule according to any one of claims 1 to 11, comprising an oligonucleotide sequence such that the anticodon stem region of the tRNA transcript is longer than that of the wild-type tRNA transcript.
Claim 14
Dependent Claim
14 words
A DNA molecule according to claim 12, comprising a DNA coding for a ribozyme.
Claim 15
Dependent Claim
17 words
A DNA molecule according to claim 13, comprising DNA coding for a ribozyme of the "hammerhead" type.
Claim 16
Dependent Claim
29 words
A DNA molecule according to any one of claims 11 to 14, comprising the DNA coding for the inhibiting RNA as an insert in an artificially introduced restriction site.
Claim 17
Dependent Claim
46 words
A DNA molecule according to claim 11 or to any one of claims 12 to 15 when dependent on claim 11, comprising an intron modified so that the secondary structure of the precursor tRNA is stabilized, whilst the structures which are critical for splicing are maintained.
Claim 18
Dependent Claim
21 words
A DNA molecule according to any one of claims 1 to 16, wherein the inhibiting RNA is directed against viral RNA.
Claim 19
Dependent Claim
32 words
A DNA molecule according to any one of claims 1 to 16, wherein the inhibiting RNA is directed against oncogenes or other key genes which control the growth or differentiation of cells.
Claim 20
Dependent Claim
43 words
A DNA molecule according to any one of claims 1 to 18 in multiple copy form wherein each copy is the same or different and each copy contains DNA coding for an inhibiting RNA molecule and is present as a complete transcription unit.
Claim 21
Dependent Claim
54 words
A process for introducing DNA molecules according to any one of claims 1 to 19 into higher eukaryotic cells, which comprises: modifying the DNA molecules so that they may be absorbed into the cells by receptor-mediated endocytosis; complexing the DNA molecules with a transferrin-polycation conjugate; and bringing the cells into contact with the complex.
Claim 22
Dependent Claim
18 words
Use of DNA molecules according to any one of claims 1 to 19 for inhibiting RNA in vivo.
Claim 23
Dependent Claim
19 words
Use according to claim 21 for inhibiting oncogenes or other key genes, which control growth or differentiation of cells.
Claim 24
Dependent Claim
9 words
Use according to claim 21 for inhibiting pathogenic viruses.
Claim 25
Dependent Claim
33 words
A pharmaceutical composition for inhibiting RNA in vivo, which comprises: (a) an effective amount of the DNA molecule according to any one of claims 1 to 19, and (b) a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
24 words
A pharmaceutical composition according to claim 24, which is used for inhibiting oncogenes or other key genes which control the growth rate of cells.
Claim 27
Dependent Claim
18 words
A pharmaceutical composition according to claim 24, which is used for inhibiting the synthesis of undesirable gene products.
Claim 28
Dependent Claim
24 words
A pharmaceutical composition according to any one of claims 24 to 26, additionally comprising a transferrin-polycation conjugate capable of complexing with the DNA molecule.
Claim 29
Dependent Claim
15 words
A pharmaceutical composition according to claim 27, wherein the transferrin-polycation conjugate is a transferrin-polylysine conjugate.
Claim 30
Dependent Claim
16 words
A pharmaceutical composition according to claim 27, wherein the transferrin-polycation conjugate is a transferrin protamine conjugate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.